Financial Performance Forecast - The company forecasts a net profit attributable to shareholders between 48 million to 52 million CNY, representing a decrease of approximately 43.37% to 38.65% compared to the previous year's profit of 84.76 million CNY[5] - The net profit attributable to the company is expected to be between 40 million to 44 million CNY, reflecting a decline of about 52.31% to 47.54% from last year's 83.87 million CNY[5] - The performance forecast is based on preliminary calculations and has not yet been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report[8] Reasons for Performance Decline - The primary reasons for the performance decline include a more than 10% decrease in sales prices of the main veterinary raw material, sulfanilamide sodium, and reduced sales volumes of crystallized sulfanilamide and diclazuril products due to decreased end-user demand[7] Non-Recurring Gains - The company recorded approximately 3.9 million CNY in government subsidies and around 4.9 million CNY in cash management income, which is an increase of about 7.76 million CNY compared to the previous year's non-recurring gains of 1.04 million CNY[7]
海昇药业(870656) - 2024 Q4 - 年度业绩预告